An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy

Trends in Pharmacological Sciences

Volumn 38, Issue 9, 2017, Pages 771-793

  Bonam, Srinivasa Reddy ^a,b   Partidos, Charalambos D ^a,d   Halmuthur, Sampath Kumar M ^b   Muller, Sylviane ^a,c  

^a INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d NONE   (United States)

Author keywords

CpG ODNs; delivery systems; lipopeptides; new adjuvants; patents; QS 21; vaccines

Indexed keywords

ADJUVANT; ALPHA GALACTOSYLCERAMIDE; ANTHRAX VACCINE; AS 01; CPG OLIGODEOXYNUCLEOTIDE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; LIPOPEPTIDE; LIPOSOME; MALARIA VACCINE; NUTHRAX; QS 21; RECOMBINANT HEPATITIS B VACCINE; WART VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; VACCINE;

CYTOKINE RESPONSE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; EMULSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; LIPOSOMAL DELIVERY; NON INVASIVE VACCINE DELIVERY; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; REVIEW; VACCINE PRODUCTION; ANIMAL; CHEMISTRY; HUMAN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; HUMANS; VACCINES;

EID: 85021342371     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2017.06.002     Document Type: Review

References (143)

1. Kaushik, D., Sehgal, D., Developing antibacterial vaccines in genomics and proteomics era. Scand. J. Immunol. 67 (2008), 544–552.
2. Leclerc, C., Ronco, J., New approaches in vaccine development. Immunol. Today 19 (1998), 300–302.
3. Nascimento, I., Leite, L., Recombinant vaccines and the development of new vaccine strategies. Braz. J. Med. Biol. Res. 45 (2012), 1102–1111.
4. Chan, Y.K., Gack, M.U., Viral evasion of intracellular DNA and RNA sensing. Nat. Rev. Microbiol. 14 (2016), 360–373.
5. Marciani, D.J., Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 8 (2003), 934–943.
6. Akira, S., et al. Pathogen recognition and innate immunity. Cell 124 (2006), 783–801.
7. Hoebe, K., et al. The interface between innate and adaptive immunity. Nat. Immunol. 5 (2004), 971–974.
8. Thompson, A.G., Thomas, R., Induction of immune tolerance by dendritic cells: implications for preventative and therapeutic immunotherapy of autoimmune disease. Immunol. Cell Biol. 80 (2002), 509–519.
9. Giannini, S.L., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 (2006), 5937–5949.
10. Tong, N.K.C., et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 68 (2005), 2298–2303.
11. Leroux-Roels, G., Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 28 (2010), C25–C36.
12. Allison, A.C., Byars, N.E., Immunological adjuvants: desirable properties and side-effects. Mol. Immunol. 28 (1991), 279–284.
13. Petrovsky, N., Aguilar, J.C., Vaccine adjuvants: current state and future trends. Immunol. Cell Biol. 82 (2004), 488–496.
14. Nalla, N., et al. Design, synthesis and immunological evaluation of 1, 2, 3-triazole-tethered carbohydrate-Pam 3 Cys conjugates as TLR2 agonists. Bioorg. Med. Chem. 23 (2015), 5846–5855.
15. Kumar, S., et al. Carbon nanotubes: a novel material for multifaceted applications in human healthcare. Chem. Soc. Rev. 46 (2017), 158–196.
16. Klinman, D.M., et al. Use of nanoparticles to deliver immunomodulatory oligonucleotides. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8 (2015), 631–637.
17. Knudsen, N.P.H., et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci. Rep., 6, 2016, 19570.
18. Buwitt-Beckmann, U., et al. Toll-like receptor 6-independent signaling by diacylated lipopeptides. Eur. J. Immunol. 35 (2005), 282–289.
19. Bessler, W.G., et al. Synthetic lipopeptide analogs of bacterial lipoprotein are potent polyclonal activators for murine B lymphocytes. J. Immunol. 135 (1985), 1900–1905.
20. Takeuchi, O., et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int. Immunol. 13 (2001), 933–940.
21. Takeuchi, O., et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J. Immunol. 169 (2002), 10–14.
22. Kang, J.Y., et al. Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer. Immunity 31 (2009), 873–884.
23. Jin, M.S., et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130 (2007), 1071–1082.
24. Borsutzky, S., et al. Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant. Vaccine 24 (2006), 2049–2056.
25. Steinhagen, F., et al. TLR-based immune adjuvants. Vaccine 29 (2011), 3341–3355.
26. Halliday, A., et al. The TLR2/6 ligand PAM2CSK4 is a Th2 polarizing adjuvant in Leishmania major and Brugia malayi murine vaccine models. Parasit. Vectors, 9, 2016, 96.
27. Cheng, C., et al. A TLR2 agonist is a more effective adjuvant for a Chlamydia major outer membrane protein vaccine than ligands to other TLR and NOD receptors. Vaccine 29 (2011), 6641–6649.
28. Zom, G.G., et al. Efficient induction of antitumor immunity by synthetic toll-like receptor ligand–peptide conjugates. Cancer Immunol. Res. 2 (2014), 756–764.
29. Sampathkumar, H.M. et al. Council of Scientific and Industrial Research. 1,2,3-triazole-tethered carbohydrate-di and tri lipidated cysteine conjugates useful as vaccine adjuvants and process for preparation thereof, 20160200758.
30. Bayik, D., et al. Structure, mechanism and therapeutic utility of immunosuppressive oligonucleotides. Pharmacol. Res. 105 (2016), 216–225.
31. Klinman, D.M., Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4 (2004), 249–259.
32. Bode, C., et al. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 10 (2011), 499–511.
33. Shirota, H., et al. CpG oligonucleotides as cancer vaccine adjuvants. Vaccines 3 (2015), 390–407.
34. Davis, H.L., et al. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160 (1998), 870–876.
35. Muraoka, D., et al. Peptide vaccine induces enhanced tumor growth associated with apoptosis induction in CD8+ T cells. J. Immunol. 185 (2010), 3768–3776.
36. Stern, B.V., et al. Vaccination with tumor peptide in CpG adjuvant protects via IFN-γ-dependent CD4 cell immunity. J. Immunol. 168 (2002), 6099–6105.
37. Bianco, A., et al. Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties. J. Am. Chem. Soc. 127 (2005), 58–59.
38. Partidos, C.D., et al. Immunomodulatory consequences of ODN CpG-polycation complexes. Methods 49 (2009), 328–333.
39. Fogg, C.N., et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25 (2007), 2787–2799.
40. Sun, S., et al. Type I interferon-mediated stimulation of T cells by CpG DNA. J. Exp. Med. 188 (1998), 2335–2342.
41. McCluskie, M.J., Davis, H.L., Cutting edge: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J. Immunol. 161 (1998), 4463–4466.
42. Chu, R.S., et al. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med. 186 (1997), 1623–1631.
43. Beignon, A.S., et al. Immunization onto bare skin with synthetic peptides: immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells. Immunology 105 (2002), 204–212.
44. Mullen, G.E., et al. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One, 3, 2008, e2940.
45. Cooper, C.L., et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 19 (2005), 1473–1479.
46. Speiser, D.E., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115 (2005), 739–746.
47. Valmori, D., et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 8947–8952.
48. Tross, D., Klinman, D.M., Effect of CpG oligonucleotides on vaccine-induced B cell memory. J. Immunol. 181 (2008), 5785–5790.
49. Minang, J.T., et al. Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909). Vaccine 32 (2014), 6847–6854.
50. Lin, A.Y., et al. Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS One, 8, 2013, e63550.
51. De Titta, A., et al. Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 19902–19907.
52. Cho, H.J., et al. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol. 18 (2000), 509–514.
53. Den Brok, M.H., et al. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. Nat. Commun., 7, 2016, 13324.
54. Richou, R., et al. Research on saponin, an adjuvant substance which stimulates immunity: I. Rev Immunol Ther Antimicrob 28 (1964), 49–62 (in French).
55. Bomford, R., Studies on the cellular site of action of the adjuvant activity of saponin for sheep erythrocytes. Int. Arch. Allergy Appl. Immunol. 67 (1982), 127–131.
56. Dalsgaard, K., Saponin adjuvants. Archiv fuer die gesamte Virusforschung 44 (1974), 243–254.
57. Soltysik, S., et al. Adjuvant activity of QS-21 Isomers. Ann. N. Y. Acad. Sci. 690 (1993), 392–395.
58. Jacobsen, N.E., et al. Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy. Carbohydr. Res. 280 (1996), 1–14.
59. Ragupathi, G., et al. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev. Vaccines 10 (2011), 463–470.
60. Eggermont, A.M., et al. Adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation after resection of primary tumor> 1.5 mm in patients with stage II melanoma: results of the EORTC 18961 randomized phase III trial. J. Clin. Oncol. 31 (2013), 3831–3837.
61. Mahmoudi, S., Keshavarz, H., Efficacy of phase 3 trial of RTS, S/AS 01 malaria vaccine in infants: a systematic review and meta-analysis. Hum. Vaccin. Immunother., 2017, 10.1080/21645515.2016.1271686 Published online January 6, 2017.
62. Rts, S., et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367 (2012), 2284–2295.
63. Kennedy, J.S., et al. The safety and tolerability of an HIV-1 DNA prime–protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 26 (2008), 4420–4424.
64. Vandepapelière, P., et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26 (2008), 1375–1386.
65. Leroux-Roels, G., et al. Vaccine Adjuvant Systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination. Vaccine 33 (2015), 1084–1091.
66. Von Eschen, K., et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum. Vaccin. 5 (2009), 475–482.
67. Vellas, B., et al. 2009) Long-term follow-up of patients immunized with AN: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6 (1792), 144–151.
68. Fernández-Tejada, A., et al. Development of a minimal saponin vaccine adjuvant based on QS-21. Nat. Chem. 6 (2014), 635–643.
69. Slovin, S.F., et al. Carbohydrate vaccines as immunotherapy for cancer. Immunol. Cell Biol. 83 (2005), 418–428.
70. Bhunia, D., et al. Design, synthesis, and evaluation of novel 1, 2, 3-triazole-tethered glycolipids as vaccine adjuvants. Archiv der Pharmazie 348 (2015), 689–703.
71. Murphy, N., et al. R-Galactosylceramides and analogues − Important immunomodulators for use as vaccine adjuvants. Carbohydr. Chem. 36 (2010), 64–100.
72. Fowlkes, B., et al. A novel population of T-cell receptor αβ-bearing thymocytes which predominantly expresses a single Vβ gene family. Nature 329 (1987), 251–254.
73. Bonifaz, L.C., et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199 (2004), 815–824.
74. Silk, J.D., et al. Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy. J. Clin. Invest. 114 (2004), 1800–1811.
75. Kim, S., et al. Glycolipid ligands of invariant natural killer T cells as vaccine adjuvants. Expert Rev. Vaccines 7 (2008), 1519–1532.
76. Laurent, X., et al. Switching invariant natural killer T (iNKT) cell response from anticancerous to anti-inflammatory effect: molecular bases: miniperspective. J. Med. Chem. 57 (2014), 5489–5508.
77. Koch, M., et al. The crystal structure of human CD1d with and without α-galactosylceramide. Nat. Immunol. 6 (2005), 819–826.
78. Zajonc, D.M., et al. Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat. Immunol. 6 (2005), 810–818.
79. Banchet-Cadeddu, A., et al. The stimulating adventure of KRN 7000. Org. Biomol. Chem. 9 (2011), 3080–3104.
80. Borg, N.A., et al. CD1d–lipid-antigen recognition by the semi-invariant NKT T-cell receptor. Nature 448 (2007), 44–49.
81. Yoshimoto, T., Paul, W.E., CD4pos, NK1.1pos T cells promptly produce interleukin 4 in response to in vivo challenge with anti-CD3. J. Exp. Med. 179 (1994), 1285–1295.
82. Carnaud, C., et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163 (1999), 4647–4650.
83. Li, X., et al. Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect. Vaccine 5 (2017), 3171–3177.
84. Verma, Y.K., et al. Design, synthesis, and immunological evaluation of benzyloxyalkyl-substituted 1, 2, 3-triazolyl α-GalCer analogues. ACS Med. Chem. Lett. 7 (2015), 172–176.
85. Hammond, K., Godfrey, D., NKT cells: potential targets for autoimmune disease therapy?. Tissue Antigens 59 (2002), 353–363.
86. Kobashi, K., et al. Down-regulation of IL-18 receptor in cancer patients: its clinical significance. Anticancer Res. 21 (2000), 3285–3293.
87. Smyth, M.J., et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191 (2000), 661–668.
88. Biron, C.A., Brossay, L., NK cells and NKT cells in innate defense against viral infections. Curr. Opin. Immunol. 13 (2001), 458–464.
89. Miyamoto, K., et al. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 413 (2001), 531–534.
90. Fujii, S.I., et al. Activation of natural killer T cells by α-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med. 198 (2003), 267–279.
91. Kopecky-Bromberg, S.A., et al. Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine. Vaccine 27 (2009), 3766–3774.
92. Gonzalez-Aseguinolaza, G., et al. Natural killer T cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med. 195 (2002), 617–624.
93. Huang, Y., et al. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide. Vaccine 26 (2008), 1807–1816.
94. Ko, S.-Y., et al. α-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor. J. Immunol. 175 (2005), 3309–3317.
95. Artiaga, B.L., et al. α-Galactosylceramide protects swine against influenza infection when administered as a vaccine adjuvant. Sci. Rep., 6, 2016, 23593.
96. Guichard, G., et al. Antigenic mimicry of natural L-peptides with retro-inverso-peptidomimetics. Proc. Natl. Acad. Sci. U. S. A. 91 (1994), 9765–9769.
97. Boeckler, C., et al. Immunogenicity of new heterobifunctional cross-linking reagents used in the conjugation of synthetic peptides to liposomes. J. Immunol. Methods 191 (1996), 1–10.
98. Tandrup Schmidt, S., et al. Liposome-based adjuvants for subunit vaccines: formulation strategies for subunit antigens and immunostimulators. Pharmaceutics, 8, 2016, 7.
99. Milicic, A., et al. Small cationic DDA: TDB liposomes as protein vaccine adjuvants obviate the need for TLR agonists in inducing cellular and humoral responses. PLoS One, 7, 2012, e34255.
100. Reed, S.G., et al. Key roles of adjuvants in modern vaccines. Nat. Med. 19 (2013), 1597–1608.
101. Saroja, C., et al. Recent trends in vaccine delivery systems: a review. Int. J. Pharm. Investig., 1, 2011, 64.
102. Beck, Z., et al. Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. Biochim. Biophys. Acta 1848 (2015), 775–780.
103. Billeskov, R., et al. Testing the H56 vaccine delivered in 4 different adjuvants as a BCG-booster in a non-human primate model of tuberculosis. PLoS One, 11, 2016, e0161217.
104. Yan, D., et al. The application of virus-like particles as vaccines and biological vehicles. Appl. Microbiol. Biotechnol. 99 (2015), 10415–10432.
105. Wang, J.W., Roden, R.B., Virus-like particles for the prevention of human papillomavirus-associated malignancies. Expert Rev. Vaccines 12 (2013), 129–141.
106. Metz, S.W., et al. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 31 (2013), 6092–6096.
107. Akahata, W., et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16 (2010), 334–338.
108. Spohn, G., et al. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol. J., 7, 2010, 146.
109. Schnurr, M., et al. ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II. J. Immunol. 182 (2009), 1253–1259.
110. Drane, D., et al. Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers. Hum. Vaccin. 5 (2009), 151–157.
111. Lövgren Bengtsson, K., et al. ISCOM technology-based Matrix M™ adjuvant: success in future vaccines relies on formulation. Expert Rev. Vaccines 10 (2011), 401–403.
112. Jacobs, C., et al. An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma. Int. J. Cancer 128 (2011), 897–907.
113. Lycke, N., From toxin to adjuvant: the rational design of a vaccine adjuvant vector, CTA1-DD/ISCOM. Cell Microbiol. 6 (2004), 23–32.
114. Fox, C.B., et al. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. Vaccine 31 (2013), 1633–1640.
115. Stavaru, C., et al. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania: preclinical evaluation of split virion inactivated H5N1 vaccine with adjuvant. Hum. Vaccin. Immunother. 12 (2016), 1009–1026.
116. ®-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir. Viruses 2 (2008), 243–249.
117. Mohan, T., et al. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J. Med. Res., 138, 2013, 779.
118. Bojang, K.A., et al. Efficacy of RTS, S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358 (2001), 1927–1934.
119. Garçon, N., et al. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6 (2007), 723–739.
120. Garçon, N., et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11 (2012), 349–366.
121. Didierlaurent, A.M., et al. AS04, an aluminum salt-and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183 (2009), 6186–6197.
122. Baldwin, S.L., et al. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J. Immunol. 188 (2012), 2189–2197.
123. Gregoriadis, G., et al. Vaccines: New Generation Immunological Adjuvants. 2012, Springer Science & Business Media.
124. Sivakumar, S., et al. Vaccine adjuvants–current status and prospects on controlled release adjuvancity. Saudi Pharm. J. 19 (2011), 197–206.
125. Petrovsky, N., Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf. 38 (2015), 1059–1074.
126. Slingluff Jr., et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21 (2003), 4016–4026.
127. Aucouturier, J., et al. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1 (2002), 111–118.
128. Miyahara, T. et al. Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute. Oil adjuvant vaccine and method for preparing same, EP 0781559 A2.
129. Pérez, O., et al. Human prophylactic vaccine adjuvants and their determinant role in new vaccine formulations. Braz. J. Med. Biol. Res. 45 (2012), 681–692.
130. Sravanthi, V., et al. Oleic acid nanoemulsion for nasal vaccination: Impact on adjuvanticity based immune response. J. Drug Deliv. Sci. Technol. 28 (2015), 56–63.
131. Holmgren, J., Czerkinsky, C., Mucosal immunity and vaccines. Nat. Med. 11 (2005), S45–S53.
132. Vajdy, M., et al. Mucosal adjuvants and delivery systems for protein-, DNA-and RNA-based vaccines. Immunol. Cell Biol. 82 (2004), 617–627.
133. Azegami, T., et al. Challenges in mucosal vaccines for the control of infectious diseases. Int. Immunol. 26 (2014), 517–528.
134. Rappuoli, R., et al. Vaccine discovery and translation of new vaccine technology. Lancet 378 (2011), 360–368.
135. Calabro, S., et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect. Vaccine 31 (2013), 3363–3369.
136. Mosca, F., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 10501–10506.
137. Didierlaurent, A.M., et al. Enhancement of adaptive immunity by the human vaccine adjuvant AS01 depends on activated dendritic cells. J. Immunol. 193 (2014), 1920–1930.
138. Garçon, N., Van Mechelen, M., Recent clinical experience with vaccines using MPL-and QS-21-containing adjuvant systems. Expert Rev. Vaccines 10 (2011), 471–486.
139. Morel, S., et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29 (2011), 2461–2473.
140. Künzi, V., et al. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration. Vaccine 27 (2009), 3561–3567.
141. ® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 23 (2005), 2530–2539.
142. Sidiq, T., et al. A novel sarsasapogenin glycoside from Asparagus racemosus elicits protective immune responses against HBsAg. Immunol. Lett. 135 (2011), 129–135.
143. Colovai, A.I., et al. Flow cytometric analysis of normal and reactive spleen. Mod. Pathol. 17 (2004), 918–927.